HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intracerebral Administration of S-Adenosylhomocysteine or S-Adenosylmethionine Attenuates the Increases in the Cortical Extracellular Levels of Dimethylarginines Without Affecting cGMP Level in Rats with Acute Liver Failure.

Abstract
Alterations in brain nitric oxide (NO)/cGMP synthesis contribute to the pathogenesis of hepatic encephalopathy (HE). An increased asymmetrically dimethylated derivative of L-arginine (ADMA), an endogenous inhibitor of NO synthases, was observed in plasma of HE patients and animal models. It is not clear whether changes in brain ADMA reflect its increased local synthesis therefore affecting NO/cGMP pathway, or are a consequence of its increased peripheral blood content. We measured extracellular concentration of ADMA and symmetrically dimethylated isoform (SDMA) in the prefrontal cortex of control and thioacetamide (TAA)-induced HE rats. A contribution of locally synthesized dimethylarginines (DMAs) in their extracellular level in the brain was studied after direct infusion of the inhibitor of DMAs synthesizing enzymes (PRMTs), S-adenosylhomocysteine (AdoHcy, 2 mM), or the methyl donor, S-adenosylmethionine (AdoMet, 2 mM), via a microdialysis probe. Next, we analyzed whether locally synthesized ADMA attains physiological significance by determination of extracellular cGMP. The expression of PRMT-1 was also examined. Concentration of ADMA and SDMA, detected by positive mode electrospray LC-DMS-MS/MS, was greatly enhanced in TAA rats and was decreased (by 30 %) after AdoHcy and AdoMet infusion. TAA-induced increase (by 40 %) in cGMP was unaffected after AdoHcy administration. The expression of PRMT-1 in TAA rat brain was unaltered. The results suggest that (i) the TAA-induced increase in extracellular DMAs may result from their effective synthesis in the brain, and (ii) the excess of extracellular ADMA does not translate into changes in the extracellular cGMP concentration and implicate a minor role in brain NO/cGMP pathway control.
AuthorsAnna Czarnecka, Krzysztof Milewski, Radosław Jaźwiec, Magdalena Zielińska
JournalNeurotoxicity research (Neurotox Res) Vol. 31 Issue 1 Pg. 99-108 (01 2017) ISSN: 1476-3524 [Electronic] United States
PMID27604291 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • RNA, Messenger
  • dimethylarginine
  • S-Adenosylmethionine
  • Arginine
  • S-Adenosylhomocysteine
  • PRMT1 protein, rat
  • Protein-Arginine N-Methyltransferases
  • Cyclic GMP
Topics
  • Animals
  • Arginine (analogs & derivatives, metabolism)
  • Cyclic GMP (metabolism)
  • Disease Models, Animal
  • Extracellular Space (metabolism)
  • Hepatic Encephalopathy (metabolism)
  • Liver Failure, Acute (metabolism)
  • Male
  • Prefrontal Cortex (metabolism)
  • Protein-Arginine N-Methyltransferases (metabolism)
  • RNA, Messenger (metabolism)
  • Rats, Sprague-Dawley
  • S-Adenosylhomocysteine (administration & dosage, metabolism)
  • S-Adenosylmethionine (administration & dosage, metabolism)
  • Signal Transduction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: